Impact of antibiotic use on survival in patients with advanced cancers treated on immune checkpoint inhibitor phase I clinical trials
Authors: S. Sen, R. Carmagnani Pestana, K. Hess, G.M. Viola, V. Subbiah
Journal: Annals of Oncology (2018)

To the Editor, The gut microbiome is a dynamic population of microorganisms that modulate both local and systemic inflammatory responses [1.Derosa L. Hellmann M.D. Spaziano M. et al.Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.Ann Oncol. 2018; 29: 1437-1444Abstract Full Text Full Text PDF PubMed Scopus (471) Google Scholar, 2.Gilbert J.A. Blaser M.J. Caporaso J.G. et al.Current understanding of the human microbiome.Nat Med. 2018; 24: 392Crossref PubMed Scopus (947) Google Scholar, 3.Vétizou M. Pitt J.M. Daillère R. et al.Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.Science. 2015; 350: 1079Crossref PubMed Scopus (1929) Google Scholar]. Antibiotic (ATB)-induced alterations in the intestinal microbiota have been characterized with expansion in the relative abundance of specific species having been noted [4.Modi S.R. Collins J.J. Relman DA. Antibiotics and the gut microbiota.J Clin Invest. 2014; 124: 4212-4218Crossref PubMed Scopus (401) Google Scholar]. Interest in the effect of the microbiome and ATB-induced dysbacteriosis in oncologic treatment outcomes has heightened with the widespread use of immune checkpoint inhibitors (ICI). Previous reports suggest a potential relevance of microbiologic factors in the clinical activity of these drugs [1.Derosa L. Hellmann M.D. Spaziano M. et al.Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.Ann Oncol. 2018; 29: 1437-1444Abstract Full Text Full Text PDF PubMed Scopus (471) Google Scholar, 3.Vétizou M. Pitt J.M. Daillère R. et al.Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.Science. 2015; 350: 1079Crossref PubMed Scopus (1929) Google Scholar, 5.Routy B. Le Chatelier E. Derosa L. et al.Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors.Science. 2018; 359: 91Crossref PubMed Scopus (2587) Google Scholar]. Derosa et al. [1.Derosa L. Hellmann M.D. Spaziano M. et al.Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.Ann Oncol. 2018; 29: 1437-1444Abstract Full Text Full Text PDF PubMed Scopus (471) Google Scholar] recently demonstrated that ATB use within 30 days of beginning ICI had a negative impact on progression-free survival (PFS) and overall survival (OS) in patients with renal cell carcinoma (RCC) and non-small-cell lung cancer (NSCLC) treated with ICI. Whether ATB use is associated with PFS and OS in patients with other advanced cancers treated on ICI remains unclear. We recently published on the development of a prognostic scoring system for patients with advanced cancer enrolled in ICI phase I clinical trials [6.Sen S. Hess K. Hong D.S. et al.Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials.Br J Cancer. 2018; 118: 763Crossref PubMed Scopus (18) Google Scholar]. Among those patients, we investigated the impact of ATB use on outcomes across tumor types in patients treated on phase I ICI trials at the MD Anderson Center from January 2013 to November 2015. Groups were compared for rate of primary progressive disease (PD), PFS, and OS. OS and PFS were estimated by the Kaplan–Meier method, and statistical significance was determined by the log-rank test. A total of 172 patients were analyzed (105 CTLA-4 based; 67 PD-1 based). Median age was 60.0 years, 49% were female. Of all patients analyzed, 38.9% were treated with ICI as a single-agent, and the remaining received combination therapy (26.7% with radiation, 18.6% with targeted therapy, and 15.7% with additional immunotherapy agents). Most common tumor types treated included RCC (14.5%), NSCLC (12.2%), melanoma (9.4%), sarcoma (9.4%), and gastrointestinal stromal tumors (5.8%). Twenty-six patients were not assessable for response; 1 patient experienced a CR and 13 patients achieved a PR (ORR = 9.5%), 57 had PD and 75 had SD as the best response. Overall, 57 patients used ATB—54 while on trial (all 54 used PO, 23 used IV as well), 19 patients in the 30-day before treatment and 14 patients 30–60 days preceding first treatment. The most commonly used ATB were quinolones (n = 39), β-lactams (n = 26), and tetracyclines (n = 7). There was no difference in the rate of primary PD with ATB use within 30 days of ICI (43% without ATB, 25% with ATB; P = 0.22) or with ATB use within 30–60 days of ICI (41% without ATB, 23% with ATB, P = 0.20). In addition, no difference was observed in PFS with ATB at all time points (Figure 1A–C). OS was significantly decreased in patients that received ATB in the 30-day before ICI initiation (Figure 1E). Our findings identify no significant difference in PFS or the rate of primary PD in patients treated on phase I ICI trials who had concurrent ATB use compared with those who did not use ATB. However, as previously reported with RCC and NSCLC, ATB use within 30 days of initiating ICI was associated with worse OS. Our results highlight the complexity of the microbiome–immune system interactions and suggest that ATB use within 30 days prior enrolling on ICI phase I trials may impact survival. Future studies are warranted to elucidate the relationship of ATB use with survival in a histology-dependent manner as these findings may have significant implications for future ICI drug development. The University of Texas MD Anderson Cancer Center is supported by the National Institutes of Health Cancer Center Support Grant CA016672. The University of Texas MD Anderson Cancer Center clinical trials program is supported in part by Cancer Prevention Research Institute of Texas Grant RP110584 and National Center for Advancing Translational Sciences Grant UL1 TR000371 (Center for Clinical and Translational Sciences).